Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

Baptiste Camus; Anne-Ségolène Cottereau; Lola-Jade Palmieri; Solène Dermine; Florence Tenenbaum; Catherine Brezault; Romain Coriat

doi:10.3390/jcm10061267

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

J Clin Med. 2021 Mar 18;10(6):1267. doi: 10.3390/jcm10061267.

Authors

Baptiste Camus^{1

2}, Anne-Ségolène Cottereau^{2

3}, Lola-Jade Palmieri^{1

2}, Solène Dermine^{1

2}, Florence Tenenbaum³, Catherine Brezault^{1

2}, Romain Coriat^{1

2}

Affiliations

¹ Gastroenterology and Digestive Oncology Unit, Cochin Hospital, AP-HP Centre, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France.
² Faculté de Médecine, Université de Paris, 75006 Paris, France.
³ Department of Nuclear Medicine, Cochin Hospital, AP-HP Centre, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France.

Abstract

Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE. Radio-peptides have been used for several years in the treatment of advanced neuroendocrine tumors. Recently, the randomized Phase III study NETTER-1 compared¹⁷⁷Lu-DOTATATE versus high-dose (double-dose) octreotide LAR in patients with metastatic midgut neuroendocrine tumors, and demonstrated its efficacy in this setting. Strong signals in favor of efficiency seem to exist for other tumors, in particular for pancreatic and pulmonary neuroendocrine tumors. This focus on radionuclide therapy in gastroenteropancreatic and pulmonary neuroendocrine tumors addresses the treatment modalities, the validated and potential indications, and the safety of the therapy.

Keywords: PRRT; gastroenteropancreatic tumor; neoplasm metastasis; neuroendocrine tumors; peptide receptor radionuclide therapy; pulmonary tumor.

Publication types

Review